What Does Delcath Systems Do?

Total employees96
HeadquartersNew York
Founded1987

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on interventional oncology. Their primary mission is to develop and commercialize innovative therapies for the treatment of primary and metastatic liver cancers. The company's proprietary system, the Delcath Hepatic Delivery System (commercially available as CHEMOSTAT® in Europe and HEPZATO™ KIT in the U.S.), is designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. This targeted approach aims to improve efficacy and reduce the side effects associated with traditional chemotherapy. Delcath is committed to advancing cancer care and addressing unmet medical needs for patients with liver-dominant cancers.

Where Is Delcath Systems's Headquarters?

HQ Function

Serves as the central hub for strategic decision-making, corporate governance, investor relations, business development, and overall operational management for its global activities in the oncology sector.

Notable Features:

Located in the Paramount Plaza building, a prominent Manhattan office skyscraper, offering access to a major business and financial hub. Internal features are modern corporate office facilities.

Work Culture:

A dynamic and focused environment, driven by innovation in the oncology field. Emphasis on scientific rigor, patient outcomes, regulatory compliance, and commercialization efforts. Collaborative atmosphere typical of biotech/pharma companies striving to bring new treatments to market.

HQ Significance:

The New York City location provides strategic advantages, including proximity to financial markets, potential partners, leading medical institutions, and a diverse talent pool. It facilitates engagement with the investment community and key stakeholders in the healthcare industry.

Values Reflected in HQ: The choice of a major metropolitan hub reflects ambition, a commitment to growth, and the need for accessibility to key resources and networks essential for a publicly-traded biopharmaceutical company with commercial products.

Location:

Delcath Systems, Inc. supports global functions primarily focused on the development, regulatory approval, and commercialization of its liver-directed therapies. This includes managing clinical trials in multiple countries, engaging with regulatory bodies such as the FDA (U.S.) and European authorities, and establishing commercial infrastructure and partnerships for product distribution in approved markets. Their primary operational focus is currently in North America (with the U.S. launch of HEPZATO™ KIT) and Europe (with CHEMOSTAT®).

Street Address:

1633 Broadway, Suite 22C

City:

New York

State/Province:

NY

Country:

United States

Where Else Does Delcath Systems Operate Around the World?

Galway, Ireland

Address: Unit 27, Briarhill Business Park, Galway, Ireland

Serves as a key hub for managing and expanding Delcath's presence in the European market, engaging with European healthcare professionals and regulatory authorities, and supporting the distribution and use of their oncology products in the region.

Buying Intent Signals for Delcath Systems

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Delcath Systems? Meet the Executive Team

As of April 2025, Delcath Systems' leadership includes:

Gerard J. D’Angelo, MD, FACP - President & Chief Executive Officer
Martha S. Rook, PhD - Chief Operating Officer
Sandra Pennell - Senior Vice President, Chief Financial Officer
Vojislav Vukovic, MD, PhD - Chief Medical Officer
Kevin Muir - Chief Commercial Officer
Johnny John, MS, RAC - Senior Vice President, Global Regulatory Affairs, Quality & Clinical Operations
Megan Po Rielly - General Counsel

Who's Investing in Delcath Systems?

Delcath Systems has been backed by several prominent investors over the years, including:

Rosalind Advisors, Inc.
Sabby Management, LLC
The Vanguard Group, Inc.
Renaissance Technologies LLC
BlackRock Inc.
Geode Capital Management, LLC

What Leadership Changes Has Delcath Systems Seen Recently?

Hire3
Exits1

Delcath Systems has significantly strengthened its leadership team over the past 12 months with key appointments including a new Chief Operating Officer, Chief Financial Officer, and General Counsel. Additionally, the Interim CEO was formally appointed as President & CEO. These changes are pivotal as the company focuses on the U.S. commercial launch of HEPZATO™ KIT and ongoing operations.

Departures

John R. Chinn, John R. Chinn resigned as Chief Financial Officer, coinciding with the appointment of Sandra Pennell as his successor.

New Appointments:

Megan Po Rielly, Megan Po Rielly appointed as General Counsel.
Sandra Pennell, Sandra Pennell appointed as SVP, Chief Financial Officer.
Martha S. Rook, PhD, Martha S. Rook, PhD, appointed as Chief Operating Officer.
Gerard J. D’Angelo, MD, FACP, Gerard J. D’Angelo, MD, FACP, transitioned from Interim CEO to permanent President & Chief Executive Officer.

What Technology (Tech Stack) Is Used byDelcath Systems?

Discover the tools Delcath Systems uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Delcath Systems Email Formats and Examples

Delcath Systems, Inc. most likely utilizes the email format of the first initial followed by the last name @delcath.com. While variations can exist within organizations, this is a common and often primary format for corporate communications.

[first_initial][last]@delcath.com

Format

gdangelo@delcath.com

Example

85%

Success rate

What's the Latest News About Delcath Systems?

Delcath Systems, Inc. Press ReleaseAugust 14, 2023

Delcath Systems Receives FDA Approval for HEPZATO™ KIT for the Treatment of Adult Patients with Metastatic Uveal Melanoma (mUM) with Unresectable Hepatic Metastases

Delcath Systems announced FDA approval for its HEPZATO KIT (melphalan/Hepatic Delivery System) for adult patients with metastatic uveal melanoma (mUM) with unresectable liver metastases. This marks a significant milestone for the company and patients with this rare and aggressive cancer....more

Delcath Systems, Inc. Press ReleaseFebruary 13, 2024

Delcath Systems Announces Commercial Launch of HEPZATO™ KIT in the U.S.

Delcath Systems announced the U.S. commercial launch of HEPZATO KIT for treating metastatic uveal melanoma (mUM). The company has initiated activities to make the therapy available to patients at trained treatment centers across the country....more

Delcath Systems, Inc. Press ReleaseMarch 19, 2024

Delcath Systems Appoints Megan Po Rielly as General Counsel

Delcath Systems announced the appointment of Megan Po Rielly as General Counsel. Ms. Rielly brings over 20 years of legal experience in the life sciences industry and will be responsible for overseeing the company's legal affairs and strategy....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Delcath Systems, are just a search away.